Vanguard Capital Management
PYXS icon

Vanguard Capital Management’s Pyxis Oncology PYXS Stock Holding History

Vanguard Capital Management’s Portfolio PYXS Stock Details PYXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.25M Buy
2,075,997
+42,487
+2% +$81.2K ﹤0.01% 3039
2026
Q1 		$2.97M Buy
+2,033,510
New +$3.06M ﹤0.01% 3241

Other funds holding PYXS

GGI
GordonMD Global Investments Beverely Hills, California $207M AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Vanguard Capital Management's PYXS Position: Q2 2026 in Review

Vanguard Capital Management increased its Pyxis Oncology (PYXS) stake by 2.1% in Q2 2026, buying an estimated $81.2K and bringing the position to 2,075,997 shares worth $6.25M. The position accounts for ﹤0.01% of the portfolio, ranked #3039.

Vanguard Capital Management first reported a position in PYXS in Q1 2026 and has held it in 2 quarters since. 76 funds tracked by Wall St. Rank hold PYXS as of Q2 2026.

  • Vanguard Capital Management held 2,075,997 shares of Pyxis Oncology worth $6.25M as of Q2 2026.
  • Vanguard Capital Management bought 42,487 Pyxis Oncology shares in Q2 2026, an estimated $81.2K.
  • Pyxis Oncology made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3039 holding.
  • Vanguard Capital Management first reported a position in Pyxis Oncology in Q1 2026 and has held it in 2 quarters since.
  • 76 funds tracked by Wall St. Rank held Pyxis Oncology as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.